Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EMA Committee Urges Warning About Hep B Reactivation In Patients Taking DAAs

Executive Summary

The European Medicines Agency’s pharmacovigilance committee wants manufacturers of the direct-acting antivirals for hepatitis C to include a warning about the possibility of hepatitis B reactivation in patients who carry both viruses.

You may also be interested in...

Direct-Acting Antivirals Slapped With Black Box On Hepatitis B Risk

FDA imposes boxed warning on labels for hepatitis C drugs in response to reports of hepatitis B reactivation, including fatal cases.

Labeling Changes Possible For HCV Direct-Acting Antivirals As EMA Probes HBV Reactivation

The European Medicines Agency has begun a review of the direct-acting antivirals (DAAs) for hepatitis C in light of a number of recent cases showing that hepatitis B virus has been reactivated in some HCV patients treated with the newer products1.

Brexit & COVID-19 Bring New Roles For UK Biological Medicines Control Lab

One effect of Brexit is that the UK’s National Institute for Biological Standards and Control will have additional responsibilities from next year in terms of the independent batch testing and release of products such as vaccines and medicines derived from human blood and plasma in Great Britain.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts